Payment overview · 2025
General Payments
$53.50
2 reported records · 2 companies
Healthcare provider profile · identity verified
Benjamin Jay Lyles, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FOREST CITY, NC · NPI 1316391436
Verified facts
What the public records show
CMS Open Payments records show Benjamin Jay Lyles, MD received $53.50 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 55.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.61 | 55.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $23.89 | 44.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $53.50 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.61 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.61 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $23.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1287 | 354 |
| Amlodipine Besylate | Amlodipine Besylate | 849 | 252 |
| Levothyroxine Sodium | Levothyroxine Sodium | 716 | 185 |
| Lisinopril | Lisinopril | 660 | 171 |
| Losartan Potassium | Losartan Potassium | 546 | 140 |
| Omeprazole | Omeprazole | 470 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 413 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 380 | 123 |
| Metformin Hcl | Metformin Hcl | 373 | 107 |
| Gabapentin | Gabapentin | 358 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 329 | 82 |
| Famotidine | Famotidine | 323 | 86 |
| Jardiance | Empagliflozin | 318 | 69 |
| Trazodone Hcl | Trazodone Hcl | 312 | 81 |
| Eliquis | Apixaban | 310 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 303 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 81 |
| Sertraline Hcl | Sertraline Hcl | 255 | 70 |
| Tramadol Hcl | Tramadol Hcl | 223 | 56 |
| Ozempic | Semaglutide | 221 | 49 |
| Lorazepam | Lorazepam | 218 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 59 |
| Carvedilol | Carvedilol | 215 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 212 | 51 |
| Furosemide | Furosemide | 210 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 205 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 203 | 60 |
| Montelukast Sodium | Montelukast Sodium | 192 | 47 |
| Potassium Chloride | Potassium Chloride | 191 | 45 |
| Glipizide | Glipizide | 190 | 53 |
| Alprazolam | Alprazolam | 188 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 171 | 46 |
| Allopurinol | Allopurinol | 163 | 47 |
| Simvastatin | Simvastatin | 163 | 43 |
| Ezetimibe | Ezetimibe | 159 | 47 |
| Mounjaro | Tirzepatide | 155 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 49 |
| Alendronate Sodium | Alendronate Sodium | 133 | 36 |
| Clonazepam | Clonazepam | 133 | 35 |
| Spironolactone | Spironolactone | 130 | 35 |
| Buspirone Hcl | Buspirone Hcl | 119 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 32 |
| Azelastine Hcl | Azelastine Hcl | 116 | 50 |
| Metformin Hcl Er | Metformin Hcl | 116 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 27 |
| Meloxicam | Meloxicam | 103 | 38 |
| Donepezil Hcl | Donepezil Hcl | 100 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 27 |
| Prednisone | Prednisone | 95 | 49 |
| Irbesartan | Irbesartan | 92 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 25 |
| Warfarin Sodium | Warfarin Sodium | 86 | 24 |
| Atenolol | Atenolol | 84 | 22 |
| Trulicity | Dulaglutide | 84 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 28 |
| Glipizide Er | Glipizide | 82 | 23 |
| Bumetanide | Bumetanide | 80 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 76 | 17 |
| Pregabalin | Pregabalin | 76 | 19 |
| Temazepam | Temazepam | 75 | 12 |
| Finasteride | Finasteride | 74 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 37 |
| Baclofen | Baclofen | 71 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 19 |
| Diazepam | Diazepam | 65 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 57 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 15 |
| Lovastatin | Lovastatin | 61 | 13 |
| Clonidine Hcl | Clonidine Hcl | 59 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 14 |
| Mirtazapine | Mirtazapine | 57 | 12 |
| Bupropion Xl | Bupropion Hcl | 56 | 18 |
| Celecoxib | Celecoxib | 56 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 13 |
| Xarelto | Rivaroxaban | 53 | 11 |
| Ondansetron Odt | Ondansetron | 52 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | suppressed |
| Glimepiride | Glimepiride | 51 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 12 |
| Enalapril Maleate | Enalapril Maleate | 48 | 12 |
| Aripiprazole | Aripiprazole | 47 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Belsomra | Suvorexant | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 36 |
| Synthroid | Levothyroxine Sodium | 43 | 15 |
| Novolog Flexpen | Insulin Aspart | 42 | 17 |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 31 |
| Colchicine | Colchicine | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 12 |
| Estradiol | Estradiol | 36 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | 11 |
| Fluconazole | Fluconazole | 35 | 30 |
| Cephalexin | Cephalexin | 33 | 16 |
| Klor-Con M20 | Potassium Chloride | 33 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | 11 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 14 |
| Nitroglycerin | Nitroglycerin | 28 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | 11 |
| Cefuroxime | Cefuroxime Axetil | 26 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 19 |
| Valsartan | Valsartan | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 15 |
| Torsemide | Torsemide | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53.50 · 2 records | ABBVIE INC. | CREON, LINZESS, Omnipod | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error